Stage-appropriate development can help lean biotech teams preserve capital, manage risk and maintain momentum without closing ...
Technology transfer creates plenty of documentation. Process descriptions, risk assessments, batch records, specifications, ...
Mike Stenberg, VP, Business Development, LGM Pharma, discusses LGM's strategic expansion, lessons learned from previous ...
Diversifying API sourcing and building qualified alternatives can help manufacturers reduce exposure to geographic ...
Understanding a CDMOs operating model under uncertainty can help determine whether it is the right partner for the program.
Biopharma companies are looking beyond available capacity to CDMO networks that can adapt across sites, scales and changing ...
For high-dose, high-concentration biologics, early alignment preserves flexibility, exposes risks before they become expensive and avoids constraints in manufacturing, clinical de ...
This week on "The Friday Brief," whether announcing a new launch or unveiling a new identity, companies generated plenty of ...
Insight on Piramal’s patient centricity initiatives and investment in Linker Payload capabilities from development to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results